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We describe a protocol for high-efficiency germline transgenesis and sustained transgene 
expression in two important biomedical models, the mouse and the rat, using the Sleeping Beauty 
transposon system.  The procedure is based on co-injection of synthetic mRNA encoding the 
SB100X hyperactive transposase together with circular plasmid DNA carrying a transgene 
construct flanked by binding sites for the transposase, into the pronuclei of fertilized oocytes. Upon 
translation of the transposase mRNA, enzyme-mediated excision of the transgene cassettes from 
the injected plasmids followed by permanent genomic insertion produces stable transgenic animals. 
Generation of a germline-transgenic founder animal by using this protocol takes approximately 
three months. Transposon-mediated transgenesis compares favorably in terms of both efficiency 
and reliable transgene expression to classic pronuclear microinjection, and offers comparable 
efficacies to lentiviral approaches, without limitations on vector design, issues of transgene 
silencing, and the toxicity and biosafety concerns of working with viral vectors. Transposition-
mediated gene delivery can easily be implemented by any laboratory, thereby providing an 
attractive method to genetically modify animals for biomedical and biotechnological purposes. 
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INTRODUCTION 
Mice and rats are the most common species used as experimental model systems for the analysis 
of physiological traits, to investigate the pathogenesis of human diseases and for developing new 
therapies. Both species offer unique advantages for use in biomedical research such as their 
versatility and the abundance of available resources, including mutant archives produced by the 
large-scale N’-ethyl-N’-nitrosourea (ENU) mutagenesis screens, the International Knockout Mouse 
Consortium (IKMC), the International Gene Trap Consortium (IGTC) and the European Mouse 
Mutant Archive (EMMA)1-6. A large number of inbred strains have been successfully generated for 
mice and rats; these genetically standardized and phenotypically characterized strains are valuable 
and well documented tools available for the scientific community. The availability of the full genome 
sequence of the mouse and the rat further strengthened their position as leading mammalian model 
organisms7,8. A comprehensive comparison with the previously decoded human genome revealed a 
high similarity in the genomic sequences presumably reflecting similarities in gene function 
between humans and rodents9.  
 The Norway rat (Rattus norvegicus) was the first mammal domesticated for scientific 
research10. Laboratory rats are widely used in pharmacological and toxicological testing but also in 
basic research for modelling physiological processes of human organ systems. Its larger size and 
often closer similarity to human biology would seem to make the rat a better experimental tool than 
the mouse (Mus musculus). However, despite the many advantages of rats as model organisms, 
the laboratory mouse is currently the predominant mammalian species in biomedical research. This 
is mainly due to the availability of several genetic modification technologies developed and 
continuously advanced in mice over the past 30 years, which enabled gene trapping and the 
introduction of targeted mutations11-15.  
 Mutagenesis is currently the most frequently used method to examine gene function and 
regulation, and several strategies have been developed to experimentally induce mutations into 
rodent germlines. Mutagenesis by homologous recombination for producing knockout and knockin 
animals was limited to mouse models owing to the successful isolation and culture of pluripotent 
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embryonic stem cells (ESCs). After more than two decades of intensive effort, pluripotent rat ESC 
lines have been successfully isolated and cultured13,16. The application of the 2i cell culture system 
developed for murine ESCs has further improved the derivation of rat ESCs17,18, and enabled for 
the first time generating a targeted mutation in the rat genome by homologous recombination19. 
However, the use of ESCs to modify the rat genome is still very challenging. Therefore, apart from 
the common technologies for genetic engineering, new strategies to manipulate the mouse and the 
rat genome have been recently developed. New tools for targeted mutagenesis that can not only be 
applied in ESCs but are efficient enough for genome engineering directly in living embryos include 
zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the 
CRISPR/Cas system20-26.  
 
Germline transgenesis in rodents 
Germline transgenesis is an important procedure for the generation of heritable, loss-of-function or 
gain-of-function phenotypes in model species for investigations into the functions of biological 
pathways as well as for animal biotechnology. Since 1981, the most routinely applied method in 
mice has been pronuclear DNA-injection27. This methodology has also been adapted to rats and is 
performed in a very similar way28,29. For mice, pronuclear injection of transgenes often yields more 
than 20% founders among the live offspring27,30. In rats the reported efficiency of classical 
microinjection is much lower than in mice, possibly due to the significantly lower percentage of ova 
surviving the microinjection procedure28,31,32. Standard pronuclear injection of a transgene involves 
the introduction of a small number of identical copies of a linearized DNA molecule into a freshly 
fertilized oocyte. Linearization of transgene constructs is important, because the integration 
frequency is much higher for linearized than for circular DNA molecules33. However, linearized 
molecules recombine with each other immediately after pronuclear injection and before 
chromosomal integration to form concatemeres34. Consequently, the gene copy number per 
transgenic locus is unpredictable and unique for each founder line. In addition, transgenic 
concatemeres can persist in a nonintegrated form for several cell divisions, resulting in unequal 
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transgene distribution between the blastomeres of the early embryo35. Therefore, a high percentage 
of transgenic founders produced by pronuclear injection are genetic mosaics36. A further limitation 
associated with this technology is that multicopy concatemers are prone to undergo transcriptional 
silencing37, thereby compromising the production of transgenic stocks with reliable spatio-temporal 
patterns of transgene expression. In addition, integration of pronuclear injected transgenes often 
causes severe chromosomal alterations at the chromosomal integration site(s), including deletions, 
duplications and translocations38-40.  
 Another alternative approach to producing transgenic rodents is sperm-mediated gene 
transfer (SMGT) combined with intracytoplasmic sperm injection (ICSI)41-43. In this procedure, 
spermatozoa are subjected to disruption of their head membranes, hence the need for the 
sophisticated ICSI for fertilization. The resulting frequency of founders produced by this technique 
is comparable to standard pronuclear injections. An improved efficiency of SMGT was 
demonstrated for large constructs cloned in YACs44. Furthermore, founders produced by SMGT are 
only rarely genetic mosaics44. However, there are major concerns regarding the impact of the 
procedure on the genetic material of the sperm and, consequently, on the genome of the resulting 
transgenic animal45,46. 
 Higher transgenic rates were reported by injecting recombinant lentiviral vectors into the 
periviteline space of ova in various animal models, including rodents and certain livestock 
species47,48. The use of lentiviral vectors for transgenesis has been optimized in rats and resulted in 
22 % average frequency of producing founders. Although this frequency certainly represents an 
improvement over classic pronuclear microinjection of naked DNA, it is much lower than the 
reported 80 % in mice47,49. Several problems with using lentiviral vectors remain, such as genetic 
mosaicism due to vector integration into the genome in later developmental stages, limitations of 
transgene size, vector-related toxicity, transcriptional silencing of proviral insertions by cellular 
mechanisms and preferential insertion into endogenous genes. Thus, methods with the capacity to 
yield more robust germline transmission rates coupled with predictable transgene expression 
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patterns, technical ease and greater safety would significantly improve transgenic studies in 
mammalian models. 
  
Transgenesis with the Sleeping Beauty transposon 
Similarly to retroviruses, DNA transposons integrate into the chromosomes of the host cells, a 
feature that forms the basis of their use for gene delivery. In nature, these elements contain a gene 
encoding a transposase enzyme flanked by inverted terminal repeats (ITRs) that carry binding sites 
for the transposase. Under laboratory conditions, transposons are applied as bi-component vector 
systems, in which a DNA sequence of interest can be cloned between the transposon ITRs and 
mobilized by providing the transposase enzyme in trans, as an expression plasmid or as in vitro 
synthesized mRNA (Fig. 1A). During transposition, the transposase excises the genetic element 
from its donor plasmid and integrates it into a chromosomal locus (Fig. 1B). Based on fossil record 
of transposons that were active >10 million years ago in diverse fish species, an ancient 
transposon was “awakened” (molecularly reconstructed) and named Sleeping Beauty (SB), after 
the Grimm brothers’ fairy tale50. SB was the first transposon shown to be capable of efficient 
transposition in vertebrate cells, thereby opening new avenues for genetic engineering in animal 
models (reviewed in ref. 51). 
 The SB system combines the advantages of retroviral vectors (permanent gene insertion 
into recipient genomes) with those of naked DNA molecules (simple and safe production and 
application). Because transposition is a cut-and-paste mechanism that does not involve reverse 
transcription, transposon-based vectors can tolerate larger and more complex transgenes. The SB 
system is not strictly limited by the size of expression cassettes52. Indeed, inserts as large as 
bacterial artificial chromosomes (BAC) were recently shown to transpose with SB at reasonable 
efficiencies in mouse ESCs53. When performing transgenesis, a single copy transgene insertion, 
which is not disturbing endogenous gene functions is desirable. Chromosomal integration of SB 
transposons is nearly random at the genome level resulting in ~60 % of the SB transposon 
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integrations being intergenic54-57. Furthermore, transposons have been shown to efficiently deliver a 
wide variety of transgene cassettes (reviewed in refs. 51, 58 and 59).  
 Because the transposase is only transiently present in the cell, the integrated transposon is 
stable (i. e., will not undergo further rounds of transposition), thereby rendering transposons easily 
controllable, conditional DNA delivery tools that can be used for versatile applications, including 
germline gene transfer. We have recently developed a hyperactive variant of the SB transposase, 
called SB100X, by in vitro evolution60. SB100X supports efficient germline transgenesis in mice60,61, 
rats61, rabbits61,62 and pigs63,64. We optimized the SB100X-mediated protocol by carefully titrating 
the relative amounts of transposase and transposon to obtain optimal rates of transgenesis to 
generate founders, and extensively evaluated it for efficacy, toxicity, mosaicism, germline 
transmission, insertion site preferences, transgene copy number and silencing. Genotyping of 
numerous transgenic lines produced by SB-transposition demonstrated single-copy integrations of 
the transposon as expected from the cut-and-paste integration reaction catalyzed by the SB-
transposase61. The numbers of integrations per genome were shown to be dependent on and 
hence controllable by the concentration of both components of the transposon system in the 
injection cocktail. The best results in terms of frequency of founder animals with mostly single 
integrations were achieved by a reduction of the amount of transposon plasmid DNA61.  
One of the most important aspects of using this protocol is that no major mosaicism was 
observed, and transgene expression was maintained for several generations in all species tested. 
The lack of mosaicism is in sharp contrast to any other current, non-viral or viral approach for 
transgenesis. This is likely due to the very nature of transgene integration: transposition results in 
precise (the ends of the integrating DNA are well defined) genomic integration of monomeric 
transgene units within a short timeframe following administration, thereby minimizing mosaicism. 
Furthermore, unlike retroviral vectors48,65-67, SB100X-catalyzed transgene integration does not 
seem to trigger transcriptional silencing56,61. Therefore, the application of the Sleeping Beauty 
transposon system described here will significantly enhance the mouse and rat genomic toolbox. 
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Limitations  
DNA transposons, including SB, are regulated by overproduction inhibition, which means that 
overexpression of the transposase has a negative effect on transposition56,68. The practical 
consequence of this phenomenon is that an optimal ratio of transposon donor plasmid and 
transposase mRNA needs to be established. As a rule of thumb, the injection mixture should 
contain 5 ng/μl SB100X mRNA and 0.4 ng/μl transposon donor plasmid for an SB vector of a total 
size of ~6.1 kb containing a ~2.5 kb transgene cassette60. For larger transgenes, the concentration 
of the donor plasmid in the microinjection mixture has to be increased to maintain optimal molar 
ratios between transposon and transposase. It has been found that embryos tolerate 
concentrations of transposon donor plasmid up to 2 ng/μl in mice60. 
 
Experimental Design 
The generation of transgenic rodents by SB-mediated transgenesis is achieved through 
microinjection of a plasmid carrying a gene of interest, cloned between the ITRs of SB, and 
synthetic transposase mRNA (Fig. 1) into the pronucleus of a fertilized oocyte, with frequencies of 
transgenic founders of 50-70% for both mice and rats61. The protocol consists of the following major 
steps: 
Preparation of Sleeping Beauty transposon components for microinjection (Steps 1-26). 
These steps include molecular cloning of a gene of interest into SB transposon vectors and 
purification of the resulting plasmid construct; preparation of mRNA encoding the transposase by in 
vitro transcription, and preparation of a nucleic acid mixture consisting of the purified transposon 
plasmid carrying the ITR-flanked transgene and the transposase mRNA. 
Transgenesis with Sleeping Beauty in mice (Steps 27-39) and rats (Steps 40-74). These steps 
include preparation of donor mice, collection of ova, microinjection of the nucleic acid mixture into 
ova and transfer of the microinjected ova into surrogate mothers.  
Genotyping of transgenic animals (Steps 75-100). These steps include PCR-based analysis of 
F0 as well as F1 offspring to establish founders and germline transmission. A simple, quick PCR 
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test can be applied to determine the presence of integrated transposon sequences from genomic 
DNA samples. The PCR primers amplify sequences in the left ITR of SB; thus, this protocol can be 
universally applied irrespective of the gene of interest that was cloned in the SB vector. In order to 
assess copy numbers of integrated transposons and map the genomic integration sites, a ligation-
mediated PCR procedure is applied69. The procedure consists of a restriction enzyme digest of the 
genomic DNA, ligation of an oligonucleotide adapter to the ends of the fragmented DNA, PCR 
amplification of a transgene/genomic DNA junction in two rounds of PCR with primers specific to 
the adapter and to the ITRs of the SB transposon, and sequencing of the junctions to map the 
insertion to the reference genome70. Finally, a locus-specific PCR is applied to distinguish and track 
the individual integrations in the F1 and later generations.  
 
MATERIALS 
Reagents 
Animals 
• Two different strains are required, the donor strain to produce ova and the recipient strain, which 
is used to provide pseudopregnant surrogate mothers. Donors: predominantly used inbred 
strains are C57BL/6 mice and F344 rats. Surrogate mothers and sterile males: recipients of 
embryos are usually outbred due to their superior fertility. Examples of preferred strains are 
NMRI and ICR mice at an age of 8-20 weeks and Wistar, Sprague Dawley and Long-Evans rats 
at an age of 11-18 weeks. ! Caution Animal experiments must be approved by and conducted 
according to institutional and national regulations. 
 
Molecular biology reagents 
• mMessage mMachine® T7 kit (Invitrogene/Ambion, cat no. AM1344) 
• Plasmid DNA preparation kit (Qiagen, cat no. 27106) 
• Agarose (DNase, RNase none detected) (Sigma–Aldrich, cat no. A4718) 
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• Ethidium bromide 1 % solution in water (Sigma–Aldrich, cat no. E7637) ! Caution This is a 
hazardous chemical. Avoid contact with skin, eyes and airways.  
• ClaI restriction endonuclease (New England Biolabs, cat no. R0179S) 
• BfaI restriction endonuclease (New England Biolabs, cat no. R0568S)  
• DpnII restriction endonuclease (New England Biolabs, cat no. R0543S) 
• Taq DNA polymerase, provided with PCR buffer (10 x) and MgCl2 (25 mM) (New England 
Biolabs, cat no. M0267S) 
• dNTP (10 mM) (New England Biolabs, cat no. N0447S) 
• Injection buffer, EmbryoMax® (Millipore, cat no. MR-095-10 F)  
• Sodium chloride (Sigma–Aldrich, cat no. S3014)  
• Sodium acetate 3 M pH 5.5 (RNase-free) (Invitrogen/Ambion, cat no. AM9740) 
• RNaseZap (Invitrogene/Ambion, cat no. AM9780) 
• 2-propanol (ROTH, cat no. 6752.1) 
• Ethanol (RNase-free) (MERCK, cat no. 108543) 
• Water (RNase-free, filtered) (Sigma–Aldrich, cat no. W4502) CRITICAL The use of filtered 
RNase-free water is recommended for solutions coming in contact with the injection material.  
• Phenol/chloroform/isoamyl alcohol, Roti®-Phenol/C/I (ROTH, cat no. A156.2) ! Caution This is a 
hazardous chemical. Avoid contact with skin, eyes and airways.  
• Chloroform/isoamyl alcohol, Roti®-C/I (ROTH, cat no. X984.2) ! Caution This is a hazardous 
chemical. Avoid contact with skin, eyes and airways.  
• Diethylpyrocarbonate (DEPC) (Sigma–Aldrich, cat no. D5758) ! Caution This is a hazardous 
chemical. Avoid contact with skin, eyes and airways.  
• 5 x TBE buffer, Nuclease-free (Sigma–Aldrich, cat no. 93306) 
• TE buffer (Sigma–Aldrich, cat no. 93283) 
• T4 DNA ligase, provided with ligase buffer (10x) (New England Biolabs, cat no. M0202S) 
• 100-bp DNA Ladder (Thermo Scientific, cat no. SM0242)  
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• 100-10.000-bp DNA Ladder (Thermo Scientific, cat no. SM0331) 
• QIAqick Gel Extraction kit (Qiagen, cat no. 28706)  
• pGEM-T Vector Systems (Promega, cat no. A3600) 
• Transposon donor plasmids are available from Addgene: pT2/BH 
(http://www.addgene.org/26556/) or pT2/HB (http://www.addgene.org/26557/). 
• Transposase expression plasmids: pCMV(CAT)T7-SB100X is available from Addgene 
(http://www.addgene.org/34879/) and pcGlobin2-SB100X is available from Dr. Zsuzsanna 
Izsvak, Max Delbrück Centrum for Molecular Medicine, Berlin. 
Animal work 
• Equine chorionic gonadotropin/Pregnant mare’s serum gonadotropin (PMSG) (Folligon®, 
Intervet, cat no. 113064 R1 or Sergon®, Bioveta a.s., reg no. 96/116/92-C) 
• Human chorionic gonadotropin (hCG) (Chorulon®, cat no. 044976 or Intervetor Pregnyl®, 
N.V.Organon, reg no. 56/279/91-C/C) 
• M2 medium (Sigma-Aldrich, cat no. M7167, St. Luis, USA) 
• M16 medium (Sigma-Aldrich, cat no. M7292) 
• G-IVF PLUS medium (Vitro Life, cat. no. 10136) 
• Mineral oil (Sigma-Aldrich, cat no. M8410-500ML) 
• Penicillin G (Sigma-Aldrich, cat no. P3032)  
• Streptomycin sulfate salt (Sigma-Aldrich, cat no. S1277) 
• Hyaluronidase (Sigma-Aldrich, cat no. H3506-100MG) 
• Ketasol® Ketamine (aniMedica, cat no. 14.057.1004) 
• Xylasol® Xylazine (aniMedica, cat no. 14.073.1011) 
• Metacam® MeloxicamXylapan (Xylazinum 20mg/ml, Vetoquinol, cat no. 96/010/01 C) 
• Narketan (Ketaminum 100 mg/ml, Vetoquinol, cat no. 96/010/01 C) 
• Eye ointment (Oleovit, Fresenius Kabi cat no. V0005652/10) 
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• Sigmacote (Sigma-Aldrich, cat no. SL2-100ML) ! Caution Corrosive, flammable, harmful in 
contact with eyes, skin and airways. 
• Sulfuric acid (Sigma-Aldrich, cat no. 320501-1L) ! Caution Corrosive, harmful in contact with 
skin. 
• Hydrofluoric acid (Sigma-Aldrich, cat no. 339261-100ML) ! Caution Corrosive, harmful in 
contact with skin. 
 
Equipment 
For molecular biology 
• Refrigerated centrifuge capable of high speed (12000 × g) (Thermo Scientific, cat no. 75008162) 
• Water bath, 37 °C (Thermo Scientific, cat no. 2824) 
• NanoDrop® ND-2000 Spectrophotometer (Thermo Scientific, cat no. 91-ND-2000) 
• Milli-Q Water Purification System (Merck Millipore, cat no. ZRXQ003T0) 
• 1.5-mL tubes, free of DNase and RNase (Eppendorf, cat no. 0030123.328) 
• Pipette tips, free of DNase and RNase [Eppendorf, cat no. 0030077.504 (0.1– 10 µl), cat no. 
0030077.539 (2–20 µl),  cat no. 0030077.555 (2–200 µl), cat no. 0030077.571 (50–1000 µl)] 
• Thermal cycler capable of temperature increments for touchdown PCR (Thermo Scientific, cat 
no. TCA0001) 
• Electrophoresis apparatus including running chamber, well combs, gel tray and power supply 
(BioRad, cat no. 164-5050) 
• 100-ml glass flask for gel preparation (SIMAX, cat no. B1812)  
Capillaries 
• Capillary tubes, length 75 mm, capacity 60 µL (KAVALIER Ltd.) 
• Borosilicate glass tubes without filament to produce transfer capillaries for embryo transfer 
(Science Products, cat no. GB150-10) ! Caution Sharp objects should be disposed into 
approved containers. 
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• Commercial injection capillaries (Femtotip II, Eppendorf, cat no. 5242957000) ! Caution Sharp 
objects should be disposed into approved containers. 
• Commercial holding capillaries (VacuTip, Eppendorf, cat no. 5175108000) ! Caution Sharp 
objects should be disposed into approved containers. 
• Glass tubes to produce injection capillaries (Narishige GD-1) ! Caution Sharp objects should be 
disposed into approved containers. 
• Glass tubes to produce holding capillaries (Narishige G-1 or G-100) ! Caution Sharp objects 
should be disposed into approved containers. 
• Pipette Puller (Sutter Instrument P-97 or Narishige PC-10)  
• Microforge (H. SAUR, cat no. A031102 or Narishige, cat no. MF-900) 
• Glass cutter (Hilgenberg, cat no. 4018303) 
 
Embryo production, microinjection and embryo transfer 
• Petri dishes 100, 60, 30 mm, sterile (Sarstedt, cat nos. 82.1474, 82.1194, 82.1135) 
• 22 µm syringe filter (Sigma-Aldrich, cat no. Z359904-50EA)  
• Stereomicroscopes with large working distance (Leica MZ 75, Leica MZ 125, SZX9 Olympus) 
• Blunt hypodermic flushing needle (32G Point Style 2 51mm, Hamilton) 
• Vibration-damped microscope table 
• Inverted microscope with DIC (Zeiss Axiovert 200 or Olympus IX70) 
• Microinjector for holding capillary (CellTram Oil, Eppendorf, cat no. 5176000025) 
• Microinjector for injection capillary (CellTram Vario, Eppendorf, cat no. 5176000033) 
• FemtoJet injector (Eppendorf, cat no. 5247 000.013) 
• Eppendorf microloader, 0.5 µL - 20 µL (Eppendorf, cat. no. 335 242 956 003) 
• 2x micromanipulator (TransferMan NK2, Eppendorf, cat no. 5188000012 or NT-88, Narishige) 
• Laminar hood (preferred with heated surface and with integrated transmission and reflecting 
microscope (IVF-Workstations, K-Systems, Kivex Biotech Ltd) 
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• Tubing with mouthpiece and capillary holder (Eppendorf, cat no. 5176 190.002) 
• Concave ground superfrost microscope slides (VWR International, cat no. 631-9475) 
• Microscope slides, 25 x 75 mm (Sigma-Aldrich, Product no. C8902-1CS) 
• Cover glass, 24 x 60 mm (Sigma-Aldrich, Product no. C9056-1CS) 
• Glue stick (KORES S.A.) 
• In vitro fertilization 4-well plate (Nunc, cat no. 144444) 
• Watchmaker forceps (07.60.05, Medicon or Sigma-Aldrich, cat no. F6521-1EA) ! Caution Sharp 
objects. 
• Surgical instruments ! Caution Sharp objects. 
• Shaving razors, stainless steel surgical prep blades (Personna, cat. no. 74-0001) ! Caution 
Sharp objects. 
• Hair clipper (Hyundai PC 550, Oster) 
• Micro-dissecting scissors (Sigma-Aldrich, cat no. S3271-1EA) ! Caution Sharp objects. 
• Nontraumatic suture material (Chirmax, EP2.5-USP, sterile, cat no. 6319) 
• Michel wound clips (Medin 7.5 x 1.75 mm, cat. no. 132 91 0391) 
• Gauze sponges 7.5 x 7.5 cm (PANEP MULLTEX DIN 61630) 
• Vliwasoft sterile dressing 7.5 x 7.5 150 ks (sterile) (Lohmann-Rauscher 12082) 
• Nontraumatic and absorbable suture material (Vicryl 6-0, V301G, Ethicon) 
• Disposable skin stapler (Precise, 3M Health Care, cat no. 78-8083-1351-0) 
 
REAGENT SETUP 
Preparation of the transposase mRNA. Synthetic mRNA encoding the SB100X transposase can 
be produced (Step 17) from either the pCMV(CAT)T7-SB100X or the pcGlobin2-SB100X 
plasmids60 (see Reagents). The latter vector supports in vitro synthesis of SB100X mRNA 
containing zebrafish β-globin 5’- and 3’-UTRs and a 30-mer synthetic poly(A) sequence, from a T7 
promoter71.  
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DEPC treatment of water. Add 1 ml DEPC to 1 L Milli-Q water to make a 0.1 % (vol/vol) solution 
and shake vigorously. Continuously stir the solution for 12 hours at room temperature (~20 °C). 
Autoclave it for 1 h to remove any trace amount of DEPC, as residual DEPC reacts with purine 
residues in RNA.  
 
NaCl solution for oligonucleotide annealing. Prepare a 500 mM NaCl stock solution in Milli-Q 
water, and sterilize with autoclaving or filtration. Prepare the working solution by diluting the stock 
10x in sterile TE buffer. Keep frozen at -20 °C. 
 
Quality control of synthetic mRNA on agarose gel. Clean the running chamber, gel tray, comb 
and flask for gel preparation with 70 % (vol/vol) ethanol and decontaminate them from RNases with 
RNaseZap. Rinse the reagent off with RNase-free Milli-Q water (DEPC-treated). Incubate 1 μl of in 
vitro synthesized mRNA in 10 μl injection buffer for 1 hour at 37 °C and run on an RNase-free 1 % 
(wt/vol) agarose gel.  
 
TBE. DEPC cannot be used directly to treat Tris buffers. To prepare TBE, dilute the nuclease-free 5 
x TBE (see Reagents) in DEPC-treated water.  
 
Hormones. Dissolve lyophilized powder of PMSG and of hCG hormones for superovulation in 
Aqua pro injectione to the final concentration of 50 IU/ml. Store solutions refrigerated (4-6 °C) for no 
longer than 2 weeks, or as frozen aliquots at -80 °C.  
 
Hyaluronidase solution. Dissolve hyaluronidase (lyophilized powder) in M2 medium to the 
concentration of 10 mg/ml (stock solution) or the working concentration of 1 mg/ml and store at -20 
°C until use. 
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Media. Prepare M2 and M16 culture media by adding Penicillin G (60 mg/L) and Streptomycin (50 
mg/L). Sterilize with a 22 µm syringe filter, aliquot and store media refrigerated (4-6 °C) for no 
longer than 4 weeks. 
 
Isolation of genomic DNA of F0 animals from tail or ear biopsies. A simple and reliable 
protocol for DNA isolation from tissue samples is available at The Jackson Laboratory page 
(http://jaxmice.jax.org/support/genotyping/tail_phenol.html).  
 
EQUIPMENT SETUP 
Chambers for microinjection. The chamber is made from a microscope slide with a 15-mm hole 
drilled in the center of the slide glued to a cover glass that forms the bottom of the chamber. Store 
the chambers in a Petri dish (diameter 100 mm) and sterilize by UV irradiation before use. 
Alternatively, use heat sterilized concave ground microscope slides.  
 
Injection and holding capillaries. Both injection and holding capillaries are commercially 
available. However, if transgenic animals are routinely generated in a laboratory, it is recommended 
to produce your own capillaries by using a puller and a microforge. The specific pulling conditions 
depend on the glass tubes and specific puller equipment used. Store the GD-1 glass tubes and 
pulled injection capillaries (with filament) in a way that avoids dust accumulation. The finely drawn 
injection capillary should have an outer diameter at the tip of about 1 μm. If the tip is sealed, push it 
slightly on the holding capillary to break the tip open. Alternatively, it can be opened prior to loading 
of the injection solution by submersing the very tip of the capillary into 20% (vol/vol) hydrofluoric 
acid for 8-12 seconds.  Stop the reaction by washing the tip in sulfuric acid for 2-3 seconds, 
followed by washing in water (biotechnology performance certified) for 2-3 seconds, and then in 
pure ethanol for 2-3 seconds. Optionally, silicon-coat the injection capillary (Sigmacote for 5-7 
seconds) and wash in water (biotechnology performance certified) for 2 to 3 seconds. Bend the tips 
of injection and holding capillaries (2-3 mm long) to an angle of 15° (using a microforge). Flame-
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polish the opposite end of the injection- and the holding-capillaries over the flame of the burner (for 
smooth insertion of capillaries into the microinstrument holders).  
 The holding capillaries are pulled with specific pulling conditions from glass tubes without 
filament (G-1, G-100). Use a microforge to break the pulled glass at an outer diameter of about 70 
μm and fire-polish the tip to an inner diameter of about 15-30 μm. If necessary, heat-sterilize both 
capillaries at 200 °C for 2 hours. 
CRITICAL The selection of optimal injection micropipettes significantly affects the speed of DNA 
injection, survival rate of injected ova, and degree of control of pronuclear injection. 
 
Hand-operated manipulation and transfer capillaries. Hand-pull transfer and manipulation 
capillaries from borosilicate glass tubes heated over the flame of a burner. Use a glass cutter to 
score the pulled segment at an internal diameter of about 300 μm (manipulation capillary) and 100 
μm (transfer capillary) (diameters are measured using the scale of a stereo microscope), then 
break and fire-polish the end. This must be done very quickly in order to avoid sealing the tip. If 
necessary, sterilize capillaries by heat or UV irradiation before use. Transfer capillaries can be used 
mouth-controlled or hand-controlled. For the latter, connect the prepared capillary with rubber 
tubing (length 1.5-2 cm, closed with a knot on one end) fitting to the diameter of pipette barrels.  
CRITICAL Selection of optimal transfer capillaries enables fast, precise, and effective manipulation 
of embryos without any damage or loss throughout the entire procedure. 
 
PROCEDURE 
CRITICAL At each step of the protocol use RNase-free plasticware and wear gloves while handling 
reagents and samples to prevent RNase contamination. 
Preparation of RNase-free transposon (ITR-flanked transgene) donor plasmid TIMING 2-4 h 
1 Clone your gene of interest between the ITRs of an SB transposon donor plasmid by standard 
molecular cloning procedures.  
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2 Transfer at least 5 μg of transposon donor plasmid in 400 μl TE buffer into a 1.5 ml tube, and 
add 400 μl phenol/chloroform/isoamyl alcohol to the tube. ! Caution This is a hazardous 
chemical. Avoid contact with skin, eyes and airways.  
3 Vortex the tube for 15 s and leave it on the bench for 2 min. Repeat this step 3 times to 
completely inactivate residual RNase. 
4 Centrifuge at 12000 × g for 5 min at room temperature. 
5 Transfer the top layer to a new, RNase-free 1.5 ml tube and add 400 µl chloroform/isoamyl 
alcohol. ! Caution This is a hazardous chemical. Avoid contact with skin, eyes and airways.  
6 Vortex for 15 s and centrifuge at 12000 × g for 5 min at room temperature. 
7 Transfer the aqueous top layer, containing the DNA, to a new, RNase-free 1.5 ml tube, add 
1/10 volume of 3 M sodium acetate and 2.5 volumes of ethanol, and precipitate the DNA  for 
30 min at -20 °C. 
8 Spin down at 12000 × g for 15 min at 4 °C and discard the supernatant. 
9 Wash the pellet in cold 70 % (vol/vol) ethanol (RNase-free) by keeping the ethanol on the 
pellet for 10 min, centrifuge at 12000 × g for 1 min at 4 °C, and discard the supernatant. 
Repeat this step to completely remove any residual chemicals that may not be tolerated by 
the embryos.  
CRITICAL STEP DEPC is not tolerated by the embryos and RNase-free solutions that come in 
contact with the injected material should be purified by filtration. Therefore, use the filtered, RNase-
free water for the preparation of 70 % ethanol.  
10 Air-dry the pellet for 5-10 minutes and resuspend it in 100 μl EmbryoMax® injection buffer.  
11 Measure the concentration of the plasmid DNA using a NanoDrop® spectrophotometer. 
12 Make a 50 ng/μl dilution of the plasmid in EmbryoMax® injection buffer. This solution can be 
used later for the preparation of the final injection mixture (Steps 25-26). 
Pause Point The plasmid stock and its 50 ng/μl dilution can be stored (preferably at -80 °C) until 
use for up to 2 years. 
 19 
13 Thaw the plasmid DNA immediately before the preparation of the microinjection mixture (Step 
25). 
 
Preparation of the transposase mRNA TIMING 10-14h 
14 Linearize at least 2 μg of the pcGlobin2-SB100X plasmid with ClaI digestion. 1 μg of 
linearized plasmid will be necessary for one round of mRNA synthesis. Check complete 
linearization on a 1 % (wt/vol) agarose gel.  
CRITICAL STEP Supercoiled plasmid DNA runs faster, whereas open circular plasmid runs slower 
on agarose gel than the linear form. Following full digestion, bands corresponding to the open 
circular and supercoiled forms of the plasmid should be no longer visible on the gel. Consequently, 
linearized plasmid DNA produces a single band corresponding to the size of the plasmid when 
compared to a linear DNA ladder size marker. 
15 Prepare the digested plasmid RNase-free by phenol/chloroform extraction as described in 
Steps 2-10. In Steps 2 and 5, set the volumes of the digested plasmid DNA, the 
phenol/chloroform/isoamyl alcohol and the chloroform/isoamyl alcohol to 100 μl each. This 
will decrease the liquid volume during precipitation and improve DNA recovery. 
16 Measure the concentration of the linearized plasmid DNA using a NanoDrop® 
spectrophotometer. 
17 Synthesize the mRNA using the mMessage mMachine® T7 kit following the manufacturer’s 
instructions.  
18 After mRNA synthesis, perform the Turbo DNase treatment and phenol/chloroform extraction 
suggested in the kit manual, with the modification that after the isopropanol precipitation 
following the phenol/chloroform extraction, wash the pellet twice in cold 70 % (vol/vol) 
ethanol. Use filtered, RNase-free water for the preparation of 70 % ethanol. Air-dry the pellet 
for 5-10 minutes.  
19 Resuspend the mRNA in 20 μl filtered, RNase-free water.  
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20 Measure the concentration of the in vitro synthesized mRNA using a NanoDrop® 
spectrophotometer. The typical yield is around 1 μg/μl. 
21 Prepare a 1 % (wt/vol) agarose gel using nuclease-free TBE buffer, Milli-Q water treated with 
DEPC and agarose powder. ! Caution DEPC is a hazardous chemical. Avoid contact with 
skin, eyes and airways.  
22 Load 1 μl of the in vitro synthesized mRNA (Step 19) in RNA loading buffer (supplied with the 
mMessage mMachine® T7 kit) and a DNA size marker and run the gel. The SB100X mRNA 
prepared using the T7 promoter on the ClaI-digested pcGlobin2-SB100X runs on a normal 
agarose gel between 700-800 bp (Fig. 2, lane 1). Typically, the in vitro synthesized mRNA 
runs as one band on a non-denaturing gel (Fig. 2, lane 1). Alternatively, two bands may be 
visible (Fig. 2, lane 2) due to the formation of secondary structures.  
? TROUBLESHOOTING 
23 Prepare 50 ng/μl dilution of the mRNA (Step 19) in EmbryoMax® injection buffer for later use. 
CRITICAL STEP It is advisable to test new batches of the EmbryoMax® injection buffer for 
accidental presence of RNase (see Reagent Setup) as the manufacturer does not guarantee that it 
is RNase-free. Fig. 2, lane 2 shows the result of an injection buffer test without visible signs of 
mRNA degradation. 
Pause Point  The in vitro synthesized mRNA and its 50 ng/μl dilutions can be stored at -80 °C until 
use. 
24 Thaw the 50 ng/μl mRNA solution immediately before the preparation of the microinjection 
mixture. 
CRITICAL STEP Repeated thawing and freezing of mRNA stocks may cause mRNA degradation. 
 
Preparation of the microinjection mixture TIMING 1h 
CRITICAL In order to prepare the final microinjection mixture, specific amounts of SB100X mRNA 
and transposon donor plasmid have to be mixed to reach their optimal final concentrations. For 
 21 
both mice and rats, the best working injection mixture contains 0.4 ng/μl transposon donor plasmid 
and 5 ng/μl SB100X mRNA60.  
25 Prepare 2X concentration solutions: 0.8 ng/μl of transposon donor plasmid (from the stock 
solution prepared in Step 12) and 10 ng/μl of transposase mRNA (from the stock solution 
prepared in EmbryoMax® injection buffer in Step 23) in EmbryoMax® injection buffer.  
26 Mix the 2X concentration solutions at 1:1 ratio to create the final microinjection mixture. 
Prepare 5-10 μl aliquots of the final microinjection mixture.  
Pause Point Aliquots of the microinjection mixture may be stored at -80 °C for a couple of months.  
 
Mouse transgenesis: Preparation of the ovum donors TIMING 3 days 
CRITICAL Mouse transgenesis is described in Steps 27-39. 
CRITICAL The staff of a transgenic lab and animal facility need to have substantial experience in 
reproductive biology, methods of assisted reproduction, cell culture techniques, mouse genetics 
and molecular biology.  
CRITICAL The animals need to be maintained and treated under conditions which are suitable in 
terms of the hygienic quality. The use of healthy animals in SPF (specific pathogen free) or SOPF 
(specific opportunistic pathogen free) conditions will assure the best results regarding efficacy of 
the method and allows for the possibility of unrestricted distribution of the resulting founders to 
other facilities. 
CRITICAL The donor strain has to be selected according to the appropriate genetic background for 
the transgene and the ability for efficient superovulation. Inbred strains are preferred, because they 
have a defined genetic background. However, they are generally less efficient in all crucial aspects 
of production of ova, microinjection and embryonic development than outbred or hybrid animals.  
27 Apply hormonal treatment to increase the number of ova per donor. Superovulate mice by 
intraperitoneal (i.p.) application of 5 IU PMSG and 46-48 h later (directly before mating) with 5 
IU hCG between 9 a.m. and 10 a.m. (Fig. 3).  
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28 Pair mice for mating. Put females into the male’s cage for mating and not vice versa. Putting 
males in a new cage may induce exploration behavior and delay the start of copulation. The 
optimal dosage of both hormones can vary depending on the mouse strain used and the age 
of the animals. 
CRITICAL STEP The most appropriate age of donors of different genetic backgrounds needs to be 
empirically determined. For example, F1-hybrid and BALB/c females are used as donors as young 
adults at about 7 weeks of age. In contrast, the superovulation of C57BL/6 females is most efficient 
as juveniles during their prepubescent stage of development.  
? TROUBLESHOOTING 
 
Isolation of ova TIMING 1 hour 
29 Equilibrate M16 medium in the incubator (at 37 °C, 5% CO2) for about 12 h before use. Pre-
warm M2 medium, mineral oil, glass slides and diluted hyaluronidase solution on a warming 
plate (37 °C) before use. Pre-warm injection anesthetics, analgesics and eye ointment to 
room temperature.  
30 In the morning of the day intended for embryo transfer to the recipient mice, harvest the ova 
from dissected oviducts of donor mice by flushing with M2 medium about 23 h after hCG 
application and mating (Fig. 3A). At this time the ova are still in or partly released from the 
cumulus complex and both pronuclei are clearly visible. 
? TROUBLESHOOTING 
31 Remove the remaining sticky cumulus cells of the flushed ova by incubation in the 1 mg/ml 
hyaluronidase solution for 3-5 min in a Petri dish. Examine the size of the pronuclei under the 
microscope, and store the ova in M2 medium on a warming plate until the pronuclei are of the 
appropriate size for injection (about 15 µm in diameter) (Step 34). The optimal time window 
for pronucleus injection lasts about 3 h from when the male pronucleus reaches 15 µm in 
diameter to shortly before the disappearance of the fully-developed pronuclei. The diameter 
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of the pronucleus can be estimated by comparing it to the diameter of the ova (which is about 
80 µm). We recommend implementation of all steps of ova preparation in a laminar flow 
bench with a 37 °C heated surface. 
CRITICAL STEP Dissect the oviduct and flush the ova in cumulus complexes immediately after 
sacrificing the donor female. Avoid changes of osmolarity due to evaporation of the medium during 
culture or injection. The resulting shrinking of the ova will complicate microinjection.  
 
Microinjection of ova  TIMING 2-3 hours 
CRITICAL RNA is very unstable and sensitive to ribonucleases. Use gloves during all steps of 
handling the injection cocktail. All materials including pipette tips, injection buffer, reaction tube, 
DNA preparations and injection capillaries have to be clean and free of ribonucleases. 
32 Place about 30 ova into the northern part of a small drop of M2 medium in the injection 
chamber (see Equipment Setup) covered by pre-warmed mineral oil. 
33 Keep the transposon DNA/transposase mRNA-injection mixture from Step 26 at 4 °C during 
usage. Fill the injection capillary with approx. 1 μl injection mixture using a microloader or by 
inverting the capillary into the injection buffer and allowing it to fill-up by capillary action. 
Ensure that the tip of the injection capillary is open. 
CRITICAL STEP Ova are not adherent to the surface of the slide and therefore need to be fixed by 
a holding capillary for injection. 
34 By using an inverted microscope and micromanipulator, select the paternal pronucleus based 
on its larger size, and fix the ovum with the holding capillary in such a way that the 
pronucleus is located near the horizontal axis of the ovum (Fig. 4). Insert the injection 
capillary into the pronucleus and inject until the pronucleus visibly swells (about 1-2 pl). The 
diameter of the pronucleus will increase from about 15 µm to 20 µm). Since the plasma 
membrane of a mouse ovum is extremely elastic, penetration usually does not occur until the 
tip of the injection capillary is inside the pronucleus. 
? TROUBLESHOOTING 
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35 Move each ovum after successful microinjection into the southern part of the oil-covered M2 
drop until all ova are treated. 
CRITICAL STEP Further details about pronuclear injection can be found in refs. 72 and 73. 
? TROUBLESHOOTING 
 
Preparation of surrogate mothers  TIMING 1-3 days 
36 Mate surrogate females monogamously or bigamously to vasectomized, sterile males of the 
same outbred stock as the females (alternatively, mutant strains expressing male infertility 
and asthenozoospermia can be used if their mating behavior is proved to be normal and if 
they produce a vaginal plug) in the afternoon of the day before microinjection (Fig. 3A), to 
produce recipients for the injected embryos on the next day. 
CRITICAL STEP Avoid pairing mice too early (e.g. in the morning) because any female mouse that 
had undergone estrus on the previous night could immediately mate and may lose the vaginal plug 
by the next morning. Since the presence of a vaginal plug is a marker for a successful mating, this 
could result in undetected pseudopregnant females. Calculate the number of matings necessary to 
provide the required number of surrogate mothers. The estrus cycle of mice is about 4 days and 
therefore 25 % of mated females are expected to have a vaginal plug. To increase the frequency of 
plugged females, they can be stimulated 48 h before mating by exposure to male pheromones 
(Whitten effect)74. This can be done with dirty bedding from the stud male’s cage. 
 
Embryo transfer  TIMING 2 hours 
37 Identify pseudopregnant recipients by vaginal plug control on the next morning after mating. 
Since the microinjection is performed in the morning, injected ova can be re-transplanted in 
the afternoon of the same day (Fig. 3A). If not enough surrogate mothers are available, the 
remaining ova can be cultured overnight in equilibrated M16 medium in an incubator and re-
transplanted the next morning as 2-cell stage embryos into 0.5 dpc pseudopregnant females. 
Use the instruments shown in Fig. 5A for embryo transfer. 
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38 Anesthetize the pseudopregnant female with 10 mg/100 g body weight of Ketamine (Ketasol) 
and 0.4 mg/100 g body weight of Xylazine (Xylasol) (Fig. 5B). Other anesthesia protocols are 
possible depending on the availability of appropriate equipment (inhalation anesthesia) or 
local regulations75. 
CRITICAL STEP Perform embryo transfer (following step) only after the animal has reached 
surgical tolerance under general anesthesia. Surgical tolerance is tested by the withdrawal reflex 
after pinching the hind foot. In order to avoid hypothermia, place the animals on a warming plate 
during surgery and until recovery from the anesthesia. Cover the eyes with eye ointment to protect 
them from drying.  
CRITICAL STEP Pseudopregnancy can be confirmed by the swollen ampulla. 
39 Transfer microinjected ova or two-cell stage embryos via the infundibulum into the oviduct as 
shown and described in Fig. 5C-K. Although there is no transmigration of mouse embryos 
from one uterine horn into the other, we recommend unilateral embryo transfer into the right 
oviduct. Transfer 20-30 injected embryos per female: too few offspring can result in bad 
brood care and infanticide by the mother. Further details about embryo transfer in mice can 
be found in refs. 73, 76 and 77. 
CRITICAL STEP In order to avoid pain after surgery, implement an appropriate analgesic treatment 
for example by subcutaneous injection of 0.05 mg meloxicam/100 g body weight.  
CRITICAL STEP Avoid exposing surrogate mothers to pheromones of an unfamiliar male for at 
least the first 4 days after embryo transfer. Exposure would have a drastic impact on the female’s 
reproductive state, and may result in termination of the early pregnancy and return of the estrus 
cyclicity (Bruce effect)78. 
? TROUBLESHOOTING 
 
Rat transgenesis: Preparation of vasectomized males  TIMING 14 days 
CRITICAL Rat transgenesis is described in Steps 40-74. 
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40 Anaesthetize male rats from outbred Long Evans stock (80 to 90 days old) with i.p. injections 
of ketamine (80 mg/kg body weight) and xylazine (4 mg/kg body weight). 
41 Shave lower abdomen with clippers and sterilize the shaved region with 70 % (vol/vol) 
ethanol. With a pair of curved forceps and scissors, make a cut across the lower abdomen 
(the incision in the midline wall should be about 1 cm wide).  
42 Using blunt forceps and scissors to separate the vas deferens from the surrounding tissue, 
gently grasp the vas deferens with the forceps, lift it out of the incision, and cut off the section 
in the loop of the vas deferens.  
43 Return the vas deferens gently back inside the abdominal cavity, and repeat the procedure 
on the other side. Sew the incision in the body wall with separate stitches and close up the 
skin with three Michel clips.  
44 Keep rats in a warm place, supervise and monitor them until they are recovered from 
anesthesia. Allow males to recover for two weeks before using them for inducing pseudo-
pregnant females. 
 
Superovulation of female donors  TIMING 3 days 
45 For stimulating of ovum donors for microinjections, select a group of 6-8 female rats (40 to 90 
days old) and inject them by an i.p. injection of 20 IU of PMSG (SERGON) in 0.4 ml of diluted 
gonadotrophin (see Reagent Setup) between 9 a.m. and 10 a.m. (Fig. 3B). 
46 For ovulation and fertilization, inject 25 IU hCG i.p. (Pregnyl) in 0.5 ml of diluted 
gonadotrophin) (see Reagent Setup) 48-49 hours after SERGON injection (Fig. 3B), transfer 
the injected rats individually into cages with a fertile male and mate them overnight.  
47 On the next morning, between 9 a.m. and 10 a.m., check rats for vaginal plugs; mark positive 
rats on the tail and place them into clean cages.  
CRITICAL STEP The day of plug observation is Day 1 of pregnancy. 
 
Recovery and manipulation of fertilized ova  TIMING 1 hour per 8 superovulated donors 
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48 Sacrifice the superovulated (donor) females with detected vaginal plugs (Step 47) by cervical 
dislocation on Day 1 of pregnancy, between 2 p.m. to 4 p.m. (Fig. 3B). Sterilize their 
abdomen with 70 % (vol/vol) ethanol and open the abdominal cavity with scissors.  
49 Hold the proximal part (about 1 mm) of the uterine horn with forceps and dissect the oviduct 
with the help of fine scissors. Wash the oviduct in 300-400 µL of M2 medium (warmed to 
room temperature) and transfer it into a 100 µL drop of M2 medium placed on the lid of a 60 
mm sterile tissue culture Petri dish (each oviduct in its individual drop of M2 medium, place 4 
oviducts separately on one lid). 
50 Place two 200 µL drops with hyaluronidase solution besides each drop with oviducts and 
transfer the Petri dish lid with oviducts under a dissecting microscope. Fix the ampulla portion 
of the oviduct with fine forceps and tear it open with second fine forceps. 
51 Release cumulus complexes with ova, transfer them (with a wide manipulation capillary) into 
the drop with hyaluronidase and incubate cumulus complexes in this drop for 3-5 minutes 
(incubate all cumulus complexes from one donor in one drop with hyaluronidase). 
52 With the help of gentle pipetting (with a narrow manipulation capillary) free ova from the 
cumulus cells, wash them in fresh M2 medium and transfer all fertilized ova into 5 µL drops of 
M2 medium placed on the bottom of the injection chamber. 
53 Place the microinjection chamber with ova under the inverted microscope (Olympus IX70, 
equipped with DIC optic, 10x eyepieces, 5x, 20x and 40x objectives). Record the number of 
fertilized ova, showing two pronuclei and a 2nd polar body. 
54 Place the injection chamber with ova under the stereomicroscope, transfer a group of ova 
collected from a single donor from the M2 medium into a drop of CO2-preincubated G-IVF 
PLUS medium at room temperature, wash them by repeated pipetting in this drop, and 
transfer them into a well (containing 300 µL of CO2-preincubated G-IVF PLUS medium) of a 
4-well plate. 
55 Keep the ova in the incubator in 6% CO2 at 37 oC for 1 to 4 hours until microinjection. 
Microinjection is done between 4 p.m. and 8 p.m. on Day 1.  
 28 
 
Pronuclear injection  TIMING 1-3 hours per 100-200 ova 
56 Place a 5 µl drop of M2 medium in the center of the microinjection chamber, and cover the 
drop with mineral oil. 
57 For DNA microinjection, transfer a group of 25-30 fertilized ova from the 4-well plate into a 
300 µL drop of M2 medium, placed on the lid of a 60 mm Petri dish, wash them and place 
them in the M2 medium drop in the microinjection chamber. 
58 Mount the chamber with ova under the inverted microscope equipped for microinjection 
(Olympus IX70 with DIC-optic, Narishige micromanipulators, FemtoJet injector and CellTram 
Air for operation of the holding microcapillary).  
59 Fill the injection capillary with 1 µL of injection mixture (Step 26) with the help of a 
microloader.  
60 Install holding and injection capillaries into basic position close to each other in the very 
center of the drop of M2 medium situated in the center of the chamber and with all ova in the 
lower half of the drop (carry out the installation at magnification 10x eyepieces and 5x 
objective). 
61 Fix a selected fertilized ovum showing distinct pronuclei and a 2nd polar body to the holding 
capillary under the DIC-optic (magnification 10x eyepieces and 20x objective), and 
microinject the ovum (Fig. 6A) so that the volume of the injected pronucleus visibly increases. 
Microinjection is done between 4 p.m and 8 p.m.; inject 100-200 ova per session (Fig. 3B). 
CRITICAL STEP Injection capillaries are changed whenever the process of microinjection is out of 
order (clogged or broken tips, increased number of lysed ova, remnants of cytoplasm or pronuclear 
membranes on the surface of microinjection capillaries). 
62 Collect all injected ova in the upper half of the working field (Fig. 6A), while the rest 
(unfertilized ova and all abnormal and degenerated ova) is left in the lower half of the field.  
? TROUBLESHOOTING 
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In vitro culture of injected ova  TIMING 15-20 hours 
63 Transfer the injection chamber with injected ova under the stereomicroscope and collect all 
surviving injected ova with a manipulation capillary. 
64 Transfer and wash the ova in a drop of CO2-preincubated G-IVF PLUS medium at room 
temperature, and place them into a well (containing 300 µL of CO2-preincubated G-IVF PLUS 
medium) of a 4-well plate. 
65 Insert the 4-well plates into the incubator in 6% CO2 at 37 oC and keep the injected ova there 
for 15 to 20 hours. 
 
Preparation of pseudopregnant recipients (surrogate mothers)  TIMING 1 day 
66 Use sexually mature Wistar female rats (90-120 days old) as foster mothers. On the day of 
microinjection (Step 61), check 10 to 40 female rats for the stage of the estrus cycle by 
vaginal flushing (between 1 p.m. and 2 p.m., Fig. 3B), and place those showing strong sign of 
proestrus (mass of nucleated epithelial cells typical for proestrus) into the cages together with 
two vasectomized Long-Evans males overnight. 
67 On the next morning, between 9 a.m. and 10 a.m., use only the rats showing vaginal plugs as 
foster mothers. Use them for embryo transfer on the same day as when vaginal plugs are 
detected (between 10 a.m. and 11 a.m., Fig. 3B).  
? TROUBLESHOOTING 
 
Embryo transfer into recipient foster mothers  TIMING 1 hour per 8 recipient foster mothers 
CRITICAL Embryo transfer of injected 2-cell embryos is done between 9 a.m. to 10 a.m. in order to 
avoid 2-cell block. To reduce the surgery trauma only unilateral transfer into the oviduct is made. 
68 Anesthetize recipient foster mother by i.p. injection of Narketan (150 mg/kg) and Xylapan (2 
mg/kg), shave the abdomen (left flank, 4 x 2 cm), sterilize with 70 % (vol/vol) ethanol and 
open the abdominal cavity (cut into skin and body wall, 1-2 cm). 
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69 Pull out the abdominal fat with the ovary, oviduct and proximal part of uterine horn and fix 
them on a strip (3 x 2 cm) of woven wound dressing soaked in saline so that the infundibulum 
is clearly visible.  
70 Place the stereomicroscope in the laminar flow box, make a hole in the ovarian bursa (with 
the help of two pairs of fine forceps and avoiding bleeding) and fix the infundibulum on a fine 
strip of paper (2 mm x 5 mm) cut off from the paper towel. 
71 Take the 4-well plate with injected embryos from the incubator (Step 65), transfer it under the 
stereomicroscope placed inside the laminar flow box, and select 2-cell embryos for the 
transfer into recipient foster mother.  
? TROUBLESHOOTING 
72 Aspirate 2-cell embryos into the manipulation capillary with narrow opening; transfer 10 to 14 
embryos to one recipient foster mother, in a minimal volume of G-IVF PLUS medium, with 
each 2-cell embryo placed between small air bubbles.  
73 Insert the manipulation capillary with 2-cell embryos into the infundibulum (close to the first 
bend of the oviduct), and gently expel the medium with 2-cell embryos into the oviduct. 
74 Gently place abdominal fat with ovary, oviduct and uterine horn back into the abdominal 
cavity, close up the abdominal wall with a suture and the skin with wound clips. Place the 
foster mother in a cage and keep her in a warm place for 1-2 hours until she wakes up and is 
mobile.  
CRITICAL STEP Avoid exposing surrogate mothers to pheromones of an unfamiliar male for at 
least the first 4 days after embryo transfer. Exposure would have a drastic impact on the female’s 
reproductive state, and may result in termination of the early pregnancy and return of the estrus 
cycle (Bruce effect)79. 
? TROUBLESHOOTING 
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Genotyping of transgenic animals by confirming transposon insertions by PCR  TIMING 
2.5 hours 
CRITICAL If the transposon includes a visibly expressed (fluorescent) marker, early embryos and F0 
offspring can be identified by fluorescence emission (Fig. 4C and Fig. 6B-D). However, transgene 
integration and germline transmission must be confirmed by DNA analysis. 
75 Isolate genomic DNA of F0 animals from tissue samples (see Reagent Setup), and set up a 
PCR reaction in a 25 μl volume containing the following components: 
Component  Amount per reaction Final  
PCR buffer (10x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Primer SB short (10 pmol/μl) (Table 1) 
Primer Tbal rev (10 pmol/μl) (Table 1) 
Genomic DNA  
Taq DNA polymerase 
H2O 
2.5 μl 
1.5 μl 
0.5 μl 
0.8 μl 
0.8 μl 
1 μl                
0.4 μl 
17.5 μl 
1x 
1.5 mM 
0.2 mM 
8 pmol  
8 pmol  
~200 ng 
2 U  
- 
 
 
 
76 Run the PCR reaction using the following conditions:  
 
 
 
 
 
 
 
77 Run a 5-μl aliquot of the PCR product on a 1 % (wt/vol) agarose gel. A PCR product of 201 
bp in length indicates the presence of genomically integrated SB transposons. An example 
result is shown in Fig. 7A.  
 
Identification of individual transgene integrations by ligation-mediated PCR (LMPCR)  
TIMING 1-2 weeks 
Cycle number Denature Anneal Extend Hold 
1 
2–31 
32 
33 
94 °C, 5 min 
94 °C, 1 min 
  
55 °C, 30 s 
  
72 °C, 30 s 
72 °C, 7 min 
  
 
 
4 °C 
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78 Digest 1 μg of genomic DNA isolated from F0 animals with BfaI, and in a separate reaction 1 
μg with DpnII (Fig. 7B), in 50 μl final volumes. Include a negative control sample (genomic 
DNA isolated from a non-transgenic animal) as well. Follow the instructions of the enzyme 
supplier. To reach complete digestion, incubate the reaction for 3 hours at 37 oC.  
CRITICAL STEP Always use high quality genomic DNA as template for PCR. Good quality 
genomic DNA runs on an agarose gel as a dominant, high molecular weight band (Fig. 7C). 
79 Add 50 μl phenol/chloroform/isoamyl alcohol to each tube. 
80 Vortex for 10 s and leave on the bench for 2 min. Repeat this step 3 times. 
81 Centrifuge the samples at 12000 × g for 5 min at room temperature. 
82 Transfer the top layer (~50 μl) to a new 1.5 mL tube and add 5 μl (1/10 volume) of sodium 
acetate and 125 μl (2.5 volumes) of ethanol, shake well and let the digested DNA precipitate 
for 30 min at -20 °C. 
83 Spin down at 12000 × g for 15 min at 4 °C, discard the supernatant.  
CRITICAL STEP The pellet is barely visible. To avoid loss of DNA, remove the liquid using a 200 μl 
pipette tip by touching only the wall of the tube that faced the inner side of the rotor.  
84 Wash the pellet in cold 70 % (vol/vol) ethanol. Keep the ethanol on the pellet for 10 min. 
85 Spin down at 12000 × g for 15 min at 4 °C, discard the supernatant.  
CRITICAL STEP The pellet is barely visible. To avoid loss of DNA remove the liquid using a 200 μl 
pipette tip by touching only the wall of the tube that faced the inner side of the rotor.  
86 Air-dry the pellet for 5-10 minutes and resuspend it in 20 μl sterile Milli-Q water.  
87 Measure the concentration of the digested DNA using a NanoDrop® spectrophotometer. The 
typical yield is between 30-50 ng/μl.   
88 To check digestion run 200 ng of each sample on a 1 % (wt/vol) agarose gel. The digested 
samples should run as a smear centered between 0.5-1 kb in size (Fig. 7D). 
Pause Point  The digested genomic DNA samples can be stored at -20 °C for up to 1 year. 
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89 Prepare the double-stranded linkers by mixing the Linker(+) oligo with the Linker(-)BfaI or 
with the Linker(-)DpnII oligo (Table 1) in separate tubes at a final concentration of 10 pmol/μl 
each in 100 μl TE buffer containing 50 mM NaCl.  
90 Place the tubes containing the oligonucleotide solutions into a boiling water bath for 2 min, 
switch off heating and leave the tubes in the bath overnight to allow a slow cool down and 
hybridization of the two single-stranded oligonucleotides to form the double-stranded linker.  
Pause Point  The annealed double-stranded oligonucleotides can be stored at -20 °C for up to 1 
year. 
91 Ligate the BfaI linkers and the DpnII linkers to the corresponding BfaI- and DpnII-digested 
genomic DNA samples, respectively (Fig. 7B). Set up the ligation reaction containing the 
components below, and incubate overnight at 16 °C. 
 
Component  Amount per reaction Final  
Ligase buffer (10x) 
BfaI- or DpnII-digested genomic DNA  
Annealed BfaI or DpnII linker (10 pmol/μl) 
T4 DNA Ligase  
H2O 
5 μl 
X μl 
2 μl 
3 μl 
X μl 
1x 
150 ng  
20 pmol 
18 U 
to final volume of 50 μl  
 
92 Set up the 1st PCR in a 50 μl reaction volume containing the components below: 
 
      
Component  Amount per reaction Final  
PCR buffer (10x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Linker Primer (10 pmol/μl) (Table 1) 
Primer Tbal rev3s (10 pmol/μl) (Table 1) 
Ligated DNA (Step 91) 
Taq DNA polymerase 
H2O 
5 μl 
3 μl 
1 μl 
1 μl 
1 μl 
2 μl 
0.5 μl 
36.5 μl 
1x 
1.5 mM 
0.2 mM 
10 pmol 
10 pmol 
- 
2.5 U 
- 
 
 
 
 
 
 
 
 
 34 
 
 
 
93 Run the 1st PCR reaction using the following conditions:  
 
 
 
 
 
 
 
 
 
 
 
 
94 Set up the 2nd PCR in a 50 μl reaction volume containing the components below: 
 
 
Component  Amount per reaction Final  
PCR buffer (10 x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Nested Primer (10 pmol/μl) (Table 1) 
Primer Tbal (10 pmol/μl) (Table 1) 
100x diluted 1st PCR sample 
Taq DNA polymerase 
H2O 
5 μl 
3 μl 
1 μl 
1 μl 
1 μl 
1 μl 
0.5 μl 
37.5 μl 
1x 
1.5 mM 
0.2 mM 
10 pmol 
10 pmol 
- 
2.5 U 
- 
 
 
 
95 Run the 2nd PCR reaction using the following conditions: 
 
 
 
 
 
 
 
 
96 Run a 10-μl aliquot of the PCR product on a 1 % (wt/vol) agarose gel. An example result is 
shown in Fig. 7E. Each band represents a transposon (transgene) genomic integration.   
? TROUBLESHOOTING 
Cycle number Denature Anneal Extend Hold 
1 
2–11 
12-36 
37 
38 
96 °C, 2 min 
92 °C, 40 s 
92 °C, 40 s 
  
60 °C -1 oC/cycle, 40 s 
50 °C, 40 s 
  
72 °C, 2 min 
72 °C, 1 min 
72 °C, 10 min 
  
 
 
 
4 °C 
Cycle number Denature Anneal Extend Hold 
1 
2–7 
8-21 
22 
23 
96 °C, 2 min 
92 °C, 40 s 
92 °C, 40 s 
  
66 °C -1 oC/cycle, 40 s 
59 °C, 40 s 
  
72 °C, 1 min 
72 °C, 1 min 
72 °C, 10 min 
  
 
 
 
4 °C 
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97 If strong, distinct bands are visible, isolate them from the gel using the QIAquick Gel 
Extraction Kit according to the manufacturer’s instructions, and sequence them. Multiple 
bands often represent multiple integrations and lower intensity bands may represent mosaic 
integrations - all of which need to be isolated from the gel, subcloned and sequenced. 
98 Map the insertion sites by a BLAT or BLAST search of the DNA sequence directly flanking 
the transposon, at the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/cgi-
bin/hgBlat) or at the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). One should be able 
to identify the TA target dinucleotides immediately flanking the ITR in the genomic sequence, 
and the BfaI and/or DpnII recognition sites where the LMPCR linkers were ligated. The PCR 
amplifications applied in parallel on the BfaI- and DpnII-digested DNA methods help the user 
to recover all integrations.  
 
Tracking individual transgene integrations by locus-specific PCR  TIMING 1 week  
99  Design primers matching the integration loci mapped in the founder mice (step 98). Avoid 
designing primers that would bind to repetitive elements and thus amplify non-specific PCR 
products. The BLAT search at the UCSC Genome Bioinformatics website directly provides a 
RepeatMasker annotation of the genomic loci where the SB transposons have integrated. 
When using BLAST at the NCBI website select “map viewer” for a given BLAST hit, then 
select “maps & options” and choose “repeats” to see the RepeatMasker annotation. After 
identification of a genomic region free of repetitive sequences in the neighborhood of the SB 
ITR, design the locus-specific primer so that its Tm is between 55-60 oC and its length is 
between 20-25 nt long. Run a BLAT or BLAST search with the new primer sequences to 
make sure that they do not bind to other genomic locations. In addition, general rules for PCR 
primer design can be found for example at 
http://www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html.  
100 Perfom the locus-specific PCR with the primer designed in Step 99 and primer Tbal (Table 
1) to trace specific transgene integrations by the presence or absence of an amplified 
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product. To maximize specificity of primer annealing to the genomic target, the use of 
touchdown PCR is recommended consisting of 5-10 touchdown cycles stepwise decreasing 
the annealing temperature by 1 oC per cycle down to the final annealing temperature, at 
about 2 °C below the Tm of the lower Tm primer, and 25 additional standard cycles. Fig. 8 
shows an example of locus-specific PCR test of a rat founder and its F1 descendants.  
 
 
 
? TROUBLESHOOTING 
Troubleshooting advice can be found in Table 2. 
 
[CE: Table 1 is in the bottom of the file.] 
 
Table 2| Troubleshooting table. 
Step Problem Possible reason Possible solution 
Step 22 Smear is detected in 
the size range lower 
than 800 bp. 
 
More than two 
bands are detected. 
RNase contamination occurred 
during or after in vitro mRNA 
synthesis. 
 
Different length products of the in 
vitro mRNA synthesis 
 
The mRNA runs aberrantly due 
to the formations of secondary 
structures  
Change solutions and maintain 
RNase-free conditions. 
 
 
Consult the troubleshooting 
instructions of the mMessage 
mMachine® T7 kit.  
Steps 27, 30 Small numbers of 
ova or unfertilized 
oocytes despite 
superovulation of 
the donors.  
Hormone treatment failed or is 
suboptimal. 
 
 
 
Age of animals is suboptimal. 
 
 
 
 
 
 
 
 
External disturbances to the 
mice during preparation of ova. 
Prepare fresh hormone solutions 
and store up to 4 weeks at -
20°C, if necessary up to 6 
months at -80 °C until use.  
 
Use females and males of 
appropriate age as described.  
 
Use experienced males. 
However, males of the inbred 
strain C57BL/6 are often bad 
breeders if their age exceeds 6 
months.  
 
Avoid cage changing or other 
activities during superovulation 
and mating of donors. 
Step 34 No visible swelling 
of the injected 
pronucleus. 
Injection capillaries clogged.  Remove remaining particles from 
the injection mixture by 
centrifuging for 10 min at 16.1 x 
g at 4 oC, and carefully transfer 
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the upper part of the injection 
solution to a fresh 1.5 mL tube 
(Steps 25-26). 
 
Pull new, clean injection 
capillaries. 
Steps 35, 62 High rate (over 20 
%) of lysed ova 
immediately or 
shortly after DNA 
microinjection. 
Shrinking due to suboptimal 
culture conditions during 
microinjection, excessive 
injection volume, or poor quality 
of injection capillaries. 
Optimize culture conditions 
during the injection procedure, 
reduce the injection pressure to 
enable better control of injection 
volume, or change the injection 
capillaries.    
Steps 39, 74 Surrogate mothers 
do not become 
pregnant. 
Surrogate mothers were 
stimulated with vasectomized 
males in an inappropriate phase 
of the estrus cycle.  
 
 
 
 
 
 
 
 
 
 
Induction of a pregnancy block 
by exposure to the pheremones 
of a foreign male (Bruce effect). 
 
Failure/inefficient establishing of 
surrogate mothers. 
 
The presence of a vaginal plug 
does not ensure 
psuedopregnancy. Therefore, 
pseudopregnancy must be 
confirmed by inspection of the 
ampulla, the ovaries and ovarian 
bursa (corpus hemorragicum and 
blood vessels, respectively) 
during embryo transfer. 
Recipients can also be pre-
selected by vaginal cytology to 
select females in proestrus for 
mating.  
 
Avoid exposing recipients to 
foreign male phermones during 
early pregnancy. 
 
Confirm pseudopregnancy of 
plugged surrogate mothers by 
the swollen ampulla. 
 
Avoid exposure of surrogate 
mothers to olfactory cues of 
foreign males. 
Steps 39, 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Small litters. Residual harmful chemicals 
remaining in the microinjection 
mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carefully washing the 
precipitated plasmid DNA and 
mRNA with 70 % ethanol (Steps 
9 and 18) is important for the 
removal of residual 
phenol/chloroform.  
 
DEPC is not tolerated by the 
ova. Consequently, RNase-free 
solutions that come in contact 
with the injected material should 
be purified by filtration.  
 
Prepare new batches of culture 
media. Test media and oil for 
toxicity by overnight culture with 
ova.  
Step 65 High rate (over 20 
%) of uncleaved ova 
after in vitro 
culturing of injected 
Suboptimal in vitro culture 
conditions, suboptimal injection 
procedure, and damage of ova 
during manipulation in vitro. 
Lowering the amount of 
DNA/mRNA mix down to 50 % of 
the original concentration in the 
injection solution (Step 26) might 
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ova. remarkably increase the number 
of 2-cell embryos suitable for 
transfer into the foster-mothers. 
Steps 77, 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low frequency of 
transgenic founders 
per litter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrity of transposase mRNA 
compromised 
 
 
 
 
 
 
 
 
 
Larger transgenes may cause a 
drop of transgenesis rates. 
 
 
 
 
 
 
Transgene detection problems, 
e. g.,  because the genomic DNA 
template used in the PCR tests 
is degraded. 
Always use RNase-free 
laboratory plastic and glassware 
and wear gloves while handling 
reagents and samples to prevent 
RNase contamination. 
 
Do not re-use injection mixture 
after microinjection due to the 
increased risk of RNase 
contamination.  
 
Increasing the amount of 
transposon (transgene) donor 
plasmid in the final injection 
mixture (preferably not over 2 
ng/μl; Step 26) may help to 
increase the efficiency in case of 
larger transgenes.  
 
Always use high-quality genomic 
DNA for PCR, as defined in Step 
78. 
 
Include a positive control (DNA 
from an established transgenic 
animal) in the PCR tests. 
 
 
TIMING 
Praparation of Sleeping Beauty transposon components for microinjection 
Steps 1-13, Preparation of RNase-free transposon (ITR-flanked transgene) donor plasmid: 2-4 h 
Steps 14-24, Preparation of the transposase mRNA: 10-14 h 
Steps 25-26, Preparation of the microinjection mixture: 1 h 
Transgenesis with Sleeping Beauty in mice  
Step 27-28, Preparation of the ovum donors: 3 days 
Steps 29-31, Isolation of ova: 1 hour 
Steps 32-35, Microinjection of ova: 2-3 hours 
Step 36, Preparation of surrogate mothers: 1-3 days 
Steps 37-39, Embryo transfer: 2 hours 
Transgenesis with Sleeping Beauty in rats 
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Steps 40-44, Preparation of vasectomized males: 14 days 
Steps 45-47, Superovulation of female donors: 3 days 
Steps 48-55, Recovery and manipulation of ova: 1 hour per 8 superovulated donors 
Steps 56-62, Pronuclear injection: 1-3 hours per 100-200 ova 
Steps 63-65, In vitro culture of injected ova: 15-20 hours 
Steps 66-67, Preparation of pseudopregnant recipients (surrogate mothers): 1 day 
Steps 68-74, Embryo transfer into recipient foster mothers: 1 hour per 8 recipient foster mothers 
Genotyping of transgenic animals 
Steps 75-77, Confirming transposon insertions by PCR: 2.5 hours 
Steps 78-98, Identification of individual transgene integration events by LMPCR: 1-2 weeks   
Steps 99-100, Tracking individual transgene integrations by locus-specific PCR: 1 week   
 
ANTICIPATED RESULTS 
The frequency of transgenic founders using SB transposon-mediated transgenesis is expected to be in 
the range of 50-70 % of live births in mice and 14-65 % in rats (Fig. 7). We found that for efficient 
transposition of a transposon of about 3 kb in length, using the optimized concentration of 0.4 ng/µl of 
plasmid and 5 ng/µl of SB100X mRNA will result in a high frequency of founders with single integration 
sites. Depending on the size of the transposon it may be necessary to modify these concentrations. The 
number of independent integration sites per genome (Fig. 8) can be more efficiently controlled by 
modifying the concentration of injected transposon donor plasmid than by modifying the concentration 
of transposase mRNA61. Lowering the concentration of transposon plasmid should lead to a decrease in 
multiple integrations. Transposon insertions are expected to be randomly distributed in the genome, 
with most transgenes located in intergenic regions. Nearly all founders produced by SB100X 
transposition are expected to transmit the transgene to the next generation. Although some differences 
in transgene expression levels and patterns between the founder lines are expected, there is no 
significant transgene silencing in the F0 and F1 generations. 
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FIGURE LEGENDS 
 
 
Figure 1. Application of Sleeping Beauty transposons for gene delivery. (A) A bi-component 
transposon system for delivering transgenes in plasmids. One component contains a gene of 
interest (GOI) cloned between the transposon inverted terminal repeats (ITR, black arrows) 
encoded by a plasmid. The other component is either a transposase expression plasmid, or 
synthetic mRNA encoding the transposase. (B) The transposon carrying a GOI is excised from the 
donor plasmid and is integrated at a chromosomal site by the transposase (purple spheres). 
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Figure 2. Result of in vitro mRNA synthesis and test of the microinjection buffer. mRNA 
quality can be determined by standard RNase-free agarose electrophoresis and ethidium bromide 
staining. Samples are run on a 1 % (wt/vol) RNase-free non-denaturing agarose gel. Lanes: M) 
DNA size marker; 1) 1 μl of in vitro synthesized mRNA; 2) 1 μl of in vitro synthesized mRNA 
incubated (1 h, 37 °C) in 10 μl EmbryoMax® injection buffer to detect the potential presence of 
RNase in the buffer (reproduced with permission from ref. 80). Shown is a result without visible 
signs of mRNA degradation. 
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Figure 3. Timelines for animal manipulations. Timing (in days) of the important protocol steps for 
mice (A) and rats (B) starting from the preparation of ova donors and ending with parturition and 
genotyping of the F0-offspring. 
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Figure 4. Overview of mouse transgenesis. (A) Inverted microscope equipped with Normarski 
optic (DCI), microinjectors for holding, and injection capillaries and micromanipulators on a 
vibration-damped microscope table. (B) Co-injection of the ITR-flanked transgene plasmid and 
transposase mRNA into the paternal pronucleus (p) of a mouse ovum fixed by a holding capillary. 
The maternal pronucleus (m) is visible but out of focus in this picture. (C) Detecting successful 
transposition and transgenesis among F0 offspring, expressing the Venus fluorescent reporter 
gene. 
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Figure 5. Equipment and steps for mouse transgenesis. (A) Specific equipment for the embryo 
transfer (2 watchmaker forceps, 2 curved dissecting forceps, sharp and blunt scissors, bulldog 
clamp, needle holder with absorbable atraumatic sutures, skin stapler, tubing with holder for the 
transfer capillary). (B) Intraperitonial injection of anesthetics to a pseudopregnant surrogate mother. 
Before she awakens from anesthesia, the mouse is treated for analgesia using a subcutaneous 
injection of Meloxicam (small picture). (C) The partially shaved and disinfected mouse in deep 
anesthesia prepared for surgery. (D) Incision of the skin about 1.5 cm-long along the dorsal midline 
below the last rib allows for access to both sides of the reproductive organs. Alternatively, separate 
incisions can be made on each flank. (E) Incision of the abdominal wall close to the visible ovary 
allows for the gentle extraction of the ipsilateral ovary, oviduct and top of the uterine horn. (F) The 
fat pad on the ovary is used to fix the female genital tract using a bulldog clamp. To reach the 
infundibulum, the bursa (a thin transparent connective tissue membrane that covers the ovaries) is 
carefully opened with two watchmaker forceps without injuring blood vessels. (G) Embryo transfer 
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is performed with a stereo microscope with about 25x magnification (o = ovary, od = oviduct, u = 
uterus). (H) Injected zygotes are transferred with a mouth controlled glass capillary directly via the 
infundibulum (i) into the oviduct. The inserted capillary is fixed with watchmaker forceps. To ensure 
correct transfer into the ampulla of the oviduct, the embryos in M2 medium are located between two 
air bubbles in the glass capillary (ab) which can be followed during the procedure. (I) After the 
transfer, the female genital tract is gently placed back into the abdominal cavity and the incision is 
closed with an abdominal suture. (J) The cut in the skin is carefully closed with suture clips. (K) 
Suture clips do not need to be removed because they are either rejected after wound healing or do 
not disturb the surrogate mother until weaning of the offspring.  
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Figure 6. Derivation of transgenic rats with a Sleeping Beauty transposon vector encoding 
the Venus fluorescent protein. (A) Pronuclear microinjection of an ovum with the help of holding 
(left) and injection (right) capillaries; ova already injected are shown in the upper part; (B) 
Blastocysts at day 5 express the Venus transgene; (C) 14-day old fetuses expressing the Venus 
transgene; (D) 2-day old transgenic rats and their nontransgenic sibs. 
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Figure 7.  Identification of transgene integration by PCR. (A) Identification of integrated transposon 
sequences from genomic DNA samples by PCR with primers that amplify the left ITR of SB. Lanes: 1) 
H2O; 2) mouse genomic DNA, negative control; 3) mouse genomic DNA, positive control; 4) transgenic 
founder #1; 5-9) F1 offspring of transgenic founder #1; 10) transgenic founder #2; 11-13) F1 offspring of 
transgenic founder #2; M) 100-bp molecular size marker. (B) Ouline of the LMPCR procedure. 
Digestion of genomic DNA with the frequently cutting restriction enzymes BfaI and DpnII and ligation of 
linkers with a known sequence allows for specific LMPCR amplification of transposon/genomic DNA 
junctions using primers specific to the transposon ITR (blue arrows) and the linkers (green arrows). 
Linker-to-linker amplifications are blocked by the 3’ amino modifications on Linker(-) oligos (Table 1)69. 
Amplification products are then sequenced and compared to the reference genome. GOI, gene of 
interest; ITR, inverted terminal repeat. (C) Agarose gel with genomic DNA samples. Lanes 1-4) genomic 
DNA samples of rat founders, 500 ng each; M) DNA size marker. (D) Agarose gel with genomic DNA 
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samples digested with BfaI restriction endonuclease. Lanes 1-4) BfaI-digested DNA samples of rat 
founders, 200 ng each; M) DNA size marker. (E) Agarose gel with LMPCR products. Lanes 1-4) result 
of nested PCR following BfaI linker ligation; M) DNA size marker.  
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Figure 8. Locus-specific PCR test of a rat founder and its F1 descendants. The founder of 
these F1 rats carried three SB integrations (in chr2, chr4 and chr16), which were transmitted to the 
13 descendants in different combinations. M, DNA size marker.  
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Table 1. Primer sequences 
 
 
 Oligo 
designation Sequence Description and use 
SB short  
 
 
5’-TACAGTTGAAGTCGGAAGTTTACATAC-3’ 
 
 
Transposon-specific 
primer used in PCR with 
Tbal rev. Step 75 
Tbal rev 
 
 
5’-GAATTGTGATACAGTGAATTATAAGTG-3’ 
 
Transposon-specific 
primer used in PCR with 
SB short. Step 75 
Linker(+) 5’-GTAATACGACTCACTATAGGGCTCCG 
CTTAAGGGAC-3’ 
Annealed either with 
Linker(-) BfaI or Linker(-) 
DpnII to form double 
stranded linker for LM-
PCR. Step 89 
Linker(-)BfaI 5’-p-TAGTCCCTTAAGCGGAG-Amino-3’ 
 
Annealed with Linker(+). 
The 3’ C7 amino 
modification prevents 
polymerase extension. 
Step 89 
Linker(-)DpnII 5’-p-GATCGTCCCTTAAGCGGAG-Amino-3’ 
 
Annealed with Linker(+). 
The 3’ C7 amino 
modification prevents 
polymerase extension. 
Step 89 
Linker Primer 5’-GTAATACGACTCACTATAGGGC-3’   
 
Linker-specific primer 
used in the first round of 
PCR with Tbal rev3s 
(transposon specific). 
Step 92 
Tbal rev3s 5’-CATGACATCATTTTCTGGAATT-3’  Transposon-specific 
primer used in the first 
round of PCR with 
Linker Primer (linker 
specific). Step 92 
Nested Primer 5’-AGGGCTCCGCTTAAGGGAC-3’   Linker-specific primer 
used in the second 
round of PCR with Tbal 
(transposon specific). 
Step 94 
Tbal 5’-CTTGTGTCATGCACAAAGTAGATGTCC-3’  Transposon-specific 
primer used in the 
second round of PCR 
with Nested Primer 
(linker specific). Step 94 
